

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**  
**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 21, 2022

**OPKO Health, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<hr/> <p><b>Delaware</b> (State or Other Jurisdiction of Incorporation)</p>	<hr/> <p><b>001-33528</b> (Commission File Number)</p>	<hr/> <p><b>75-2402409</b> (IRS Employer Identification No.)</p>
<hr/> <p><b>4400 Biscayne Blvd.      Miami, Florida</b> (Address of Principal Executive Offices)      <b>33137</b> (Zip Code)</p>		

Registrant's telephone number, including area code: (305) 575-4100

**Not Applicable**

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	OPK	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     

---

**ITEM 5.02.      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 21, 2022, Dr. Robert Fishel notified OPKO Health, Inc. (the “Company”), that he was retiring from service on the Company’s Board of Directors (the “Board”), effective January 21, 2022. Dr. Fishel previously served as a director of the Company since April 2018. At the time of his resignation, Dr. Fishel served on the Compensation Committee and the Succession Committees and was the chair of the Independent Investment Committee of the Board.

Dr. Fishel’s resignation is not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

Date: January 24, 2022

By: /s/ Steven D. Rubin

Name: Steven D. Rubin

Title: Executive Vice President-Administration